Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

219.72 -11.46 (-4.96%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

These 3 Funds Offer Sky-High Yields of 15% or More and Trade at a Discount ↗

April 30, 2025

Via The Motley Fool

BridgeBio's Pfizer-Rivaling Heart Drug Just Obliterated Sales Expectations ↗

April 29, 2025

The company sells a rival to Pfizer' heart treatment, Vyndaqel. Sales smashed expectations in its first quarter on the market.

Via Investor's Business Daily

Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

April 28, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Demystifying Alnylam Pharmaceuticals: Insights From 15 Analyst Reviews ↗

March 11, 2025

Via Benzinga

$1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today ↗

March 03, 2025

Via Benzinga

How Do Investors Really Feel About Alnylam Pharmaceuticals? ↗

April 21, 2025

Via Benzinga

Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results

April 17, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 15 Years ↗

April 15, 2025

Via Benzinga

Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks ↗

April 04, 2025

Trump's new tariff move may raise U.S. pharma costs, with analysts warning of risks tied to EU manufacturing and shifting healthcare policies.

Via Benzinga

Topics Government World Trade

Is Alnylam Pharmaceuticals Gaining or Losing Market Support? ↗

April 04, 2025

Via Benzinga

Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference

April 01, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

27 Analysts Assess Alnylam Pharmaceuticals: What You Need To Know ↗

March 31, 2025

Via Benzinga

If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today ↗

March 31, 2025

Via Benzinga

FDA Approves Sanofi's Hemophilia Drug ↗

March 31, 2025

FDA approves Sanofi's Qfitlia, the first antithrombin-lowering therapy for hemophilia A or B, reducing bleeding episodes with as few as six injections per year.

Via Benzinga

Competitive Analysis In The ATTR-CM Field ↗

March 30, 2025

Precision medicine was proved in the ATTR-CM field. We think acoramidis is a more potent TTR stabilizer and that it will attract first-line patients. Tafamidis, acoramidis and vutrisiran will share the...

Via Talk Markets

Topics Stocks / Equities

Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology’s Annual Scientific Session 2025

March 29, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

FDA Approves Qfitlia™ (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B

March 28, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Pharmaceuticals Presents 'Convincing Multi-Billion Dollar Opportunity': Analyst Upgrades Stock ↗

March 24, 2025

Alnylam's Amvuttra wins FDA approval for ATTR-CM, expanding its market reach. JP Morgan upgrades the stock, projecting strong sales and a multi-billion opportunity.

Via Benzinga

Carnival To Rally Around 48%? Here Are 10 Top Analyst Forecasts For Monday ↗

March 24, 2025

Via Benzinga

Robinhood, Roku And Shopify Are Among Top 10 Large-Cap Gainers Last Week (Mar 17-Mar 21): Are The Others In Your Portfolio? ↗

March 23, 2025

Best performing large-cap stocks last week: Alnylam Pharma up 16%, Roku up 14%, Elbit Systems up 13%, Venture Global up 12%, Boeing up 11%. Are they in your portfolio?

Via Benzinga

Alnylam Jumps As A New Approval Sets Up Its Next Battle With Pfizer, BridgeBio ↗

March 21, 2025

Alnylam added a gene silencer to the cardiomyopathy space this week, and will now rival Pfizer and BridgeBio.

Via Investor's Business Daily

Alnylam's Amvuttra Secures FDA Approval For Expanded Use For Rare Heart Disease, Stock Jumps ↗

March 21, 2025

Alnylam's Amvuttra receives FDA approval for ATTR-CM, expanding its use and securing broad insurance coverage as global regulatory reviews continue.

Via Benzinga

Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)

March 20, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

How Do Investors Really Feel About Alnylam Pharmaceuticals? ↗

March 14, 2025

Via Benzinga

Alnylam to Webcast Presentation at Stifel 2025 Virtual CNS Forum

March 11, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary

March 05, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 20 Years ↗

February 26, 2025

Via Benzinga

Alnylam Highlights Significant Pipeline Progress and Platform Innovation at R&D Day

February 25, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Coinbase To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

February 18, 2025

Via Benzinga

Alnylam Delivers a Big Q4 Earnings Beat ↗

February 13, 2025

Alnylam Pharmaceuticals exceeded Wall Street's expectations with strong revenue growth and significant commercial progress.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.